BMN673

Catalog No. A11243

BMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity.
  • Charles-André Philip, .et al. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors, BMC Cancer, 2017, 17: 638 PMID: 28886696
Catalog Num A11243
M. Wt 380.35
Formula C19H14F2N6O
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 1207456-01-6
Synonyms BMN-673, BMN 673
SMILES CN1C(=NC=N1)[[email protected]@H]2[[email protected]](N=C3C=C(C=C4C3=C2NNC4=O)F)C5=CC=C(C=C5)F
BMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity.
Targets
PARP (Cell-free assay)
0.58 nM
In vitro DMSO 76 mg/mL heating (199.81 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 26.29 mL 131.46 mL 262.92 mL
0.5 mM 5.26 mL 26.29 mL 52.58 mL
1 mM 2.63 mL 13.15 mL 26.29 mL
5 mM 0.53 mL 2.63 mL 5.26 mL

*The above data is based on the productmolecular weight 380.35. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.